Apx Acquisition CORP I 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
APX Acquisition Corp. I will be delisted from the Nasdaq Stock Market after failing to complete a business combination within the required timeframe.
APX Acquisition Corp. I has extended its deadline to complete a business combination to December 9, 2025, and modified redemption terms following shareholder approval at an extraordinary general meeting.
APX Acquisition Corp. I has entered into a promissory note agreement for $700,000 with Bioceres LLC, carrying a 20% annual interest rate, to fund working capital and business combination expenses.
APX Acquisition Corp. I has received notice that its warrants and units will be delisted from Nasdaq due to non-compliance with listing rules, while its Class A ordinary shares will remain listed.
APX Acquisition Corp. I received a notice from Nasdaq for failing to maintain the minimum market value for its outstanding warrants, putting them at risk of delisting.
APX Acquisition Corp. I has terminated its agreement to acquire MultiplAI Health Ltd due to financial and regulatory concerns, but will proceed with the merger with OmnigenicsAI Corp.
APX Acquisition Corp. I has issued a $446,000 promissory note to Bioceres LLC with a 20% annual interest rate, to be repaid upon the completion of its business combination.
APX Acquisition Corp. I received a notice from Nasdaq for failing to file its 2023 annual report and Q1 2024 report, putting its listing status at risk.
APX Acquisition Corp. I filed an amendment to its 8-K report to provide further details on director independence and committee appointments following recent board changes.
APX Acquisition Corp. I has announced the resignation of two directors and the appointment of a new independent director, Daniel Mudd, who will chair the audit committee.
APX Acquisition Corp. I reports the resignation of a director and the appointment of two new directors, effective April 6, 2024.
APX Acquisition Corp. I has entered into a definitive agreement to combine with OmnigenicsAI Corp and MultiplAI Health Ltd, creating a new publicly traded entity focused on AI-driven healthcare solutions.
APX Acquisition Corp. I has entered into a definitive agreement to merge with OmnigenicsAI and MultiplAI Health, creating a global AI-driven genomics platform.
Templar Subco LLC, a subsidiary of APX Acquisition Corp. I's sponsor, has joined existing letter and registration rights agreements following a transfer of shares.
APX Acquisition Corp. I reports the resignation of two directors and the appointment of a new director, effective immediately on March 8, 2024.
APX Acquisition Corp. I has increased its working capital facility to $2 million through an amended promissory note with Templar LLC, which can be converted into warrants upon a business combination.
APX Acquisition Corp. I has announced the resignation of Daniel Braatz as CEO and Chairman, with Kyle Bransfield appointed to both roles, effective immediately.
APX Acquisition Corp. I has successfully extended its deadline to complete a business combination by up to twelve months, following shareholder approval at an extraordinary general meeting.
APx Acquisition Corp. I amends its letter agreement and trust agreement, extends its business combination deadline, and sees a change in share ownership and board composition.